Disparity in actions of rosiglitazone against cisplatin-induced nephrotoxicity in female Sprague-Dawley rats

Environmental Toxicology and Pharmacology

Volumn 36, Issue 3, 2013, Pages 883-890

  Kumar, Parveen ^a   Prashanth, Krishna Shastrula ^a   Gaikwad, Anil Bhanudas ^b   Vij, Mohit ^c   Barua, Chandana C ^d   Bezbaruah, Babul ^a  

^a GAUHATI MEDICAL COLLEGE   (India)

^b BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

^c Government College of Pharmacy   (India)

^d Pandit Deen Dayal Upadhayay Pashu Chikitsa Vigyan Vishwa Vidyalaya Evum Go Anusandhan Sansthan   (India)

Author keywords

Cisplatin; Inflammation; Nephrotoxicity; Posttreatment; Pretreatment; Rosiglitazone

Indexed keywords

ALBUMIN; CISPLATIN; CREATININE; CYTOKINE; NITROGEN; PROTEIN BAX; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UREA;

ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY WEIGHT; CISPLATIN INDUCED NEPHROTOXICITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG MECHANISM; FEMALE; HISTOPATHOLOGY; KIDNEY CORTEX; KIDNEY INJURY; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; UREA NITROGEN BLOOD LEVEL;

CISPLATIN; INFLAMMATION; NEPHROTOXICITY; POSTTREATMENT; PRETREATMENT; ROSIGLITAZONE;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD UREA NITROGEN; BODY WEIGHT; CISPLATIN; CREATININE; FEMALE; HYPOGLYCEMIC AGENTS; KIDNEY; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; ORGAN SIZE; RATS; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN; THIAZOLIDINEDIONES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84883592600     PISSN: 13826689     EISSN: 18727077     Source Type: Journal    
DOI: 10.1016/j.etap.2013.08.004     Document Type: Article

References (28)

1. Aisner J., Jacobs M., Sinabaldi V., Gray W., Eisenberger M. Chemoradiotherapy for the treatment of regionally advanced head and neck cancers. Semin. Oncol. 1994, 21:35-44.
2. Arany I., Safirstein R.L. Cisplatin nephrotoxicity. Semin. Nephrol. 2003, 23:460-464.
3. Barak Y., Nelson M.C., Ong E.S., Jones Y.Z., Ruiz-Lozano P., Chien K.R., Koder A., Evans R.M. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol. Cell 1999, 4:585-595.
4. Basnakian A.G., Apostolov E.O., Yin X., Napirei M., Mannherz H.G., Shah S.V. Cisplatin nephrotoxicity is mediated by deoxyribonuclease I. J. Am. Soc. Nephrol. 2005, 16:697-702.
5. Celi F.S., Shuldiner A.R. The role of peroxisome proliferator-activated receptor gamma in diabetes and obesity. Curr. Diab. Rep. 2002, 2:179-185.
6. Cuzzocrea S., Pisano B., Dugo L., Ianaro A., Maffia P., Patel N.S., di Paola R., Ialenti A., Genovese T., Chatterjee P.K., di Rosa M., Caputi A.P., Thiemermann C. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation. Eur. J. Pharmacol. 2004, 483:79-93.
7. Desvergne B., Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 1999, 20:649-688.
8. Faubel S., Lewis E.C., Reznikov L., Ljubanovic D., Hoke T.S., Somerset H., Oh D.J., Lu L., Klein C.L., Dinarello C.A., Edelstein C.L. Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. J. Pharmacol. Exp. Ther. 2007, 322:8-15.
9. Hsueh W.A., Jackson S., Law R.E. Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes. Diabetes Care 2001, 24:392-397.
10. Jiang C., Ting A.T., Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391:82-86.
11. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 2007, 7:573-584.
12. Kota B.P., Huang T.H., Roufogalis B.D. An overview on biological mechanisms of PPARs. Pharmacol. Res. 2005, 51:85-94.
13. Lee S., Kim W., Moon S.O., Sung M.J., Kim D.H., Kang K.P., Jang Y.B., Lee J.E., Jang K.Y., Park S.K. Rosiglitazone ameliorates cisplatin-induced renal injury in mice. Nephrol. Dial. Transplant. 2006, 21:2096-2105.
14. Lemberger T., Desvergne B., Wahli W. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu. Rev. Cell Dev. Biol. 1996, 12:335-363.
15. Li S., Gokden N., Okusa M.D., Bhatt R., Portilla D. Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF. Am. J. Physiol. Renal Physiol. 2005, 289:F469-F480.
16. Luo Y., Yin W., Signore A.P., Zhang F., Hong Z., Wang S., Graham S.H., Chen J. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J. Neurochem. 2006, 97:435-448.
17. Ozkaya O., Yavuz O., Can B., Dilek M., Savli E., Acikgoz Y., Bedir A., Akpolat T. Effect of rosiglitazone on cisplatin-induced nephrotoxicity. Ren. Fail. 2010, 32:368-371.
18. Ramesh G., Reeves W.B. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J. Clin. Invest. 2002, 110:835-842.
19. Ramesh G., Reeves W.B. Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-alpha. Kidney Int. 2004, 65:490-499.
20. Schrier R.W. Cancer therapy and renal injury. J. Clin. Invest. 2002, 110:743-745.
21. Suzuki T., Hayashi S., Miki Y., Nakamura Y., Moriya T., Sugawara A., Ishida T., Ohuchi N., Sasano H. Peroxisome proliferator-activated receptor gamma in human breast carcinoma: a modulator of estrogenic actions. Endocr. Relat. Cancer 2006, 13:233-250.
22. Tikoo K., Bhatt D.K., Gaikwad A.B., Sharma V., Kabra D.G. Differential effects of tannic acid on cisplatin induced nephrotoxicity in rats. FEBS Lett. 2007, 581:2027-2035.
23. Tikoo K., Meena R.L., Kabra D.G., Gaikwad A.B. Change in post-translational modifications of histone H3, heat-shock protein-27 and MAP kinase p38 expression by curcumin in streptozotocin-induced type I diabetic nephropathy. Br. J. Pharmacol. 2008, 153:1225-1231.
24. Tikoo K., Ali I.Y., Gupta J., Gupta C. 5-Azacytidine prevents cisplatin induced nephrotoxicity and potentiates anticancer activity of cisplatin by involving inhibition of metallothionein, pAKT and DNMT1 expression in chemical induced cancer rats. Toxicol. Lett. 2009, 191:158-166.
25. Tikoo K., Kumar P., Gupta J. Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7,12-dimethyl benz{a}anthracene (DMBA) induced breast cancer rats. BMC Cancer 2009, 9:107.
26. Wu Y.M., Zhang K.J., Yue X.T., Wang Y.Q., Yang Y., Li G.C., Li N., Wang Y.G. Enhancement of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying MDA-7/IL-24. Acta Pharmacol. Sin. 2009, 30:467-477.
27. Yao X., Panichpisal K., Kurtzman N., Nugent K. Cisplatin nephrotoxicity: a review. Am. J. Med. Sci. 2007, 334:115-124.
28. Zhang B., Ramesh G., Norbury C.C., Reeves W.B. Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. Kidney Int. 2007, 72:37-44.